CRL

Complete response letter (CRL) reflects the FDA’s comprehensive review of the data submitted in an original or abbreviated application, including any amendments reviewed by the agency. The CRL identifies any outstanding issues and specifies the reasons the application will not be approved in its present form, as outlined in §§ 314.125 or 314.127.